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OBJECTIVE: To study if metformin, when administered to first-degree relatives of type 2 diabetes mellitus subjects who have 
metabolic syndrome and normal glucose tolerance, could improve the cardiovascular risk profile and reduce the levels of both 
C-reactive protein and fibrinogen.
INTRODUCTION: Metabolic syndrome is associated with higher cardiovascular morbidity and mortality. Metformin has vasculo-
protective effects even in normoglycemic subjects, and C-reactive protein and fibrinogen are considered markers of endothelial 
injury and inflammation. 
METHODS: Thirty-one non-diabetic first-degree relatives of type 2 diabetes mellitus subjects with metabolic syndrome were 
randomized (1:1) and double-blinded for placement in the placebo and metformin groups (850mg bid/±90days); 16 subjects were 
administered metformin (mean age 40.0 [33.5-50] years; 13 females) and 15 subjects were in the placebo group (mean age 37.0 
[32-42] years; 9 females). Blood samples were collected at baseline and at the end of treatment for biochemical analyses, including 
an assessment of C-reactive protein and fibrinogen levels.
RESULTS: Metformin improved the lipid profile and decreased fasting plasma glucose, systolic blood pressure, weight and body 
mass index without changing body composition. For those in the placebo we identified no changes in fibrinogen (282.2 [220.4-
323.7] mg/L vs. 286.7 [249.6-295.1] mg/L; NS) or in C-reactive protein levels (0.68 [0.3-1.2] vs. 0.64 [0.3-1.0] mg/L; NS). The 
same was also observed for the levels of fibrinogen (303.9 [217.6-347.6] mg/L vs. 290.9 [251.5-301.9] mg/L; NS) and C-reactive 
proteins (0.78 [0.3-1.1] vs. 0.80 [0.4-0.9] mg/L; NS) in the metformin group. 
CONCLUSIONS: Metformin treatment in first-degree relatives of type 2 diabetes mellitus sufferers who have metabolic syn-
drome and normal glucose tolerance improved the cardiovascular risk profile without changing the levels of C-reactive protein 
and fibrinogen.
KEYWORDS: Metformin; Fibrinogen; C-reactive protein; Normoglycemia; Metabolic syndrome.
INTRODUCTION
Metabolic syndrome (MS) is a pre-diabetic state that 
embodies factors implicated in cardiovascular (CV) risk, 
including dyslipidemia, hypertension, impaired glucose 
tolerance (IGT) or type 2 diabetes mellitus (T2DM), insulin 
resistance (IR) and abdominal obesity.1 Among these, 
abdominal obesity is the major component and possibly even 
the pathophysiological cornerstone of CV disease. Excessive 
accumulation of visceral adipose tissue directly increases 
CV morbidity and mortality.2 There is a clear link between 
markers of inflammation, MS, and atherosclerosis.2
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Acute phase proteins are markers of inflammatory 
systemic response, and their plasma concentrations increase 
or decrease by at least 25 percent during an inflammatory 
challenge. C- reactive protein (CRP) and fibrinogen, 
both defined as acute-phase proteins, are associated with 
atherosclerosis, metabolic disorders, and CV disease.3 
Visceral obesity increases the concentration of 
plasminogen activator inhibitor type-1 (PAI-1), which is an 
inhibitor of t-PA (activator of plasminogen to plasmin).4 Its 
inhibition results in a relative imbalance of fibrinolytic factors, 
which is associated with greater risk of thrombosis and higher 
risk of CV events.5 Higher levels of fibrinogen, a zymogen that 
is activated to fibrin in blood clotting, are associated with MS6 
and T2DM,7 but also with subclinical CV disease.8 
CRP, a predictor of early atherosclerotic damage,9 
is related to high adiposity (mainly abdominal), IR and 
dyslipidemia. It directly promotes endothelial activation and 
impairs nitric oxide (NO) production, resulting in endothelial 
dysfunction.10 Elevated CRP is also a marker of low-grade 
inflammation, especially when associated with visceral 
adipose tissue11 and macrophage infiltration of the adipose 
tissue.10,11 Adipocytokines may induce the production of CRP 
by the liver. 
The biguanide metformin is an orally administered 
drug that lowers blood glucose in patients with T2DM 
by improving insulin sensitivity and suppressing hepatic 
gluconeogenesis.12 It also reduces CV morbidity and 
mortality in overweight T2DM subjects13 and, additionally, 
can lower the incidence rate of T2DM and MS in subjects 
with IGT.14,15 However, even in normoglycemic subjects, 
there are also some clinical and experimental data that 
support its pleiotropic effects, mainly those related to 
vascular tissue.16 We have previously demonstrated its 
beneficial action in MS normoglycemic patients on both 
endothelial17 and skin nutritive microvascular reactivity.18 
What still deserves investigation is whether markers of 
endothelial imbalance like CRP and fibrinogen may be used 
as markers of the beneficial effects of metformin in metabolic 
disorders. Our aim is to investigate if metformin acts on 
some classical markers of the CV risk profile, like the lipid 
profile, blood pressure, and fasting plasma glucose (FPG), 
and whether fibrinogen and CRP may be used as indirect 
markers of its action in first-degree relatives of T2DM 
subjects who have MS and normal glucose tolerance.
MATERIALS AND METHODS
All subjects were selected from the outpatient care 
facility of the State University of Rio de Janeiro. Thirty-one 
first-degree relatives of T2DM subjects who exhibit MS 
and normal glucose tolerance were recruited to the study, 
and they were randomly divided into placebo (n=15) and 
metformin (n=16) groups (Table 1). All subjects gave their 
written informed consent and our local Ethics Committee 
approved the protocol.
Anthropometric, clinical and laboratory measurements
The same trained examiner collected anthropometric 
measurements in duplicate at baseline and at the end of the 
treatment period. These included the waist size at its smallest 
point with the abdomen relaxed, and the body weight as 
measured using a digital scale (Filizola, São Paulo, SP, 
Brazil). Body mass index (BMI) was defined as a patient’s 
Table 1 - Clinical, anthropometric and body composition characteristics of both groups at baseline and after treatment
Placebo Metformin
Baseline After treatment Baseline After treatment
Gender (F/M) 9/6 - 13/3 -
Age (years) 37 [32-42] - 40 [33.5-50] -
Known hypertension 7[46.7%] - 8[50%] -
Anti-hypertensive drug use 5 [33%] - 6[37.5%] -
Weight (kg) 100.3 [84.6-109.9] 102.2† [86.2-111.6] 83.5 [78.6-96.7] 82.5* [77.5-96.4]
BMI (kg/m2) 36.7 [34.3-40.2] 37.2† [33.9-41.1] 34.2 [29.8-39.5] 33.6* [30.1-38.3]
Waist (cm) 104 [98-112] 105 [96-113] 97.5 [90.5-104.5] 97.5 [92.5-105.5]
Systolic BP 140 [126-149] 140 [124-145] 143 [123.5-149.5] 133.5* [124-141.5]
Diastolic BP 84.0 [75-91] 83.0 [71-88] 80.5 [73-87.5] 78.0 [72-87.5]
Fat Mass (%) 42.0 [37.0-46.0] 41.0 [35.0-45.0] 40.5 [38.0-43.0] 40.0 [35.5-43.0]
Fat Free Mass (%) 58.0 [54.0-63.0] 59.0 [55.0-65.0] 59.5 [57.0-62.0] 60.0 [57.0-64.5]
Data expressed as medians (1st-3rd quartiles). † p < 0.05 - comparisons within placebo group. *p < 0.05; ** p < 0.01 – comparisons within metformin 
group.
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weight in kilograms divided by squared height in meters. 
Body composition was analyzed using Vcorp software 
with QUANTUM II equipment (RJL systems Inc, USA), 
and required four measurements in duplicate. Mean values 
were used for analysis. Blood pressure (BP) was measured 
twice, with a five minute interval, at rest in the supine 
position, using an automated apparatus (Multiparameter 
patient monitor - Lifewindow LW6000, Digicare Biomedical 
Technology, West Palm Beach, FL, USA).
All laboratory measurements were performed in 
duplicate, after a 10-12 h fast, using an automated method 
(Modular Analytics PP, Roche, Basel, Switzerland). Mean 
values were used at analysis. Fasting and post-load plasma 
glucose, total cholesterol, triglycerides and high-density 
lipoprotein (HDL) cholesterol were measured, respectively, 
by enzyme-colorimetric GOD-PAP (inter-assay coefficient 
of variation (IECV) = 1.09%;), enzymatic GPO-PAP (IECV 
= 2.93%), enzymatic GPO-PAP (IECV = 1.29%) and 
enzyme-colorimetric method without pre-treatment (IECV 
= 3.23%). Plasma low-density lipoprotein (LDL) cholesterol 
was calculated according to the Friedwald equation. 
Fibrinogen (IECV = 4.33%) and CRP (IECV = 2.66%) were 
measured, respectively, using the coagulometric method and 
imunoturbidimetry with the modular Analytics P (ROCHE®) 
system. Insulin was monitored by electrochemiluminescence 
(IECV=10.6%,) and the homeostasis model assessment 
(HOMA-IR) was calculated to quantify insulin resistance.19 
Study Design
During the first clinical visit, patients were subjected to a 
physical examination and were given a 75-g oral anhydrous 
glucose tolerance test (fasting and at 2 hours), a lipid profile 
assessment, and CRP and fibrinogen determination after a 
10- to 12-hour fast. All subjects enrolled exhibited normal 
glucose tolerance test results according to the ADA criteria20 
and met at least three criteria for MS according to NCEP-
ATPIII.1 
The main exclusion criteria were pregnancy, T2DM or 
any degree of glucose intolerance, smoking, major illnesses, 
a history of previous myocardial infarction or angina 
pectoris, a post-menopausal history, and the use of oral 
contraceptives, aspirin, or statins.
Subjects were randomized 1:1 in a double-blinded 
fashion, in order to compare metformin to placebo. Pills 
were taken for at least 90 days. During the first week 
of treatment, only the dinner pill was taken, in order to 
minimize gastrointestinal side effects. After this period, pills 
were administered at lunch and at dinnertime. Metformin 
pills were prepared with 850 mg/pill by Merck-Santé, Lyon, 
France. Compliance was reconfirmed every 30 days. All 
subjects were asked to maintain their usual diet and physical 
activity. Antihypertensive drugs remained unchanged during 
the study. 
Statistical Analysis
Comparisons between groups at baseline and after the 
treatment period were performed using the Mann-Whitney 
U test and the Wilcoxon matched pair tests, respectively. 
Frequency comparisons for the 2x2 tables were made 
with Yates corrected Chi-squared test. Differences noticed 
after the treatment period were transformed to percent of 
increment or decrement, and associations between these and 
the decrements in weight and BMI in the metformin group 
were assessed using a Spearman correlation. Sample size had 
not been calculated in advance and, as a consequence, the 
power of the reported analysis should be considered relevant 
only for the population studied. Significant differences were 
assumed to be present in cases when p<0.05. All group data 
are reported as the median [1st - 3rd quartiles].
RESULTS
Study population
There was no difference between the number of days 
of treatment for the placebo and metformin groups (109 
[101-112] vs. 102.2 [97-112.5] days, p=0.21). Mean and 
maximum durations of treatment for the placebo and 
metformin groups were 106.7/116 and 102.5/116 days, 
respectively. Almost 50% of subjects in both groups had a 
known history of hypertension, and there was no difference 
between the groups in respect of this metric. At baseline, 
anthropometric, clinical, laboratorial and body composition 
measurements were no different between groups, except in 
the case of insulin and HOMA-IR (Table 2) data.
Anthropometric, clinical and laboratory data after 
treatment
There were no changes in either clinical or laboratory 
measurements in the placebo group, except for increasing 
weight and BMI (Table 1). The metformin group, however, 
had a decrease in weight, BMI, systolic BP, total and LDL-
cholesterol and FPG (Tables 1 and 2) without changes in 
body composition (Table 1). The metformin group also 
exhibited increased HDL-cholesterol levels (Table 2). The 
two groups exhibited the same levels of CRP and fibrinogen 
at baseline (Table 2). After the treatment period, neither 
group had a CRP or fibrinogen level that was different from 
baseline (Table 2). 
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Associations in the metformin group between decrements 
in weight and BMI and decrements in FPG, total and LDL-
cholesterol and triglycerides, and increased HDL-cholesterol 
were tested, and there was no correlation between them.
DISCUSSION
Our findings demonstrate that short-term use of 
metformin in first-degree relatives of T2DM subjects who 
have MS and normal glucose tolerance promotes weight 
loss, an improved lipid profile, and better systolic BP and 
FPG (even within the normoglycemic range). CRP and 
fibrinogen are two acute-phase response proteins seen in 
inflammation,3 and both are also associated with low-grade 
inflammation and atherogenesis. It was reasonable to suppose 
that metformin, a drug widely used in T2DM patients that 
exerts known protective effects on the vascular wall16-18 and 
the inflammatory state,21 would result in reduced levels of 
these two pivotal markers of inflammation and endothelial 
imbalance. However, this effect was not observed after the 
treatment period. 
Metformin may directly impact the pathophysiology 
of athero-thrombosis, because in T2DM subjects its short-
term use improved markers of endothelial dysfunction and 
inflammatory activity.21 Since higher levels of adiposity are 
associated with low-grade inflammation, we expected that by 
losing weight and improving the CV risk profile, the use of 
metformin in MS subjects would change CRP and fibrinogen 
levels. This hypothesis could not be proved; therefore, these 
parameters should not be considered markers of CV disease 
risk response in our group.
The National Cholesterol Education Program’s Adult 
Treatment Panel III report (NCEP-ATP III) classified 
MS as including six components related to CV disease: 
abdominal obesity, atherogenic dyslipidemia, raised BP, 
a pro-inflammatory state, a pro-thrombotic state, and IR1. 
Abdominal obesity, clinically presented as an increased 
waist circumference, is a major component of the MS and 
is linked to CV risk. This is due to an increase in several 
products, including nonesterified fatty acids (NEFA), 
cytokines, PAI-1, and lowered adiponectin levels.22,23 The 
proinflammatory and prothrombotic states found in the MS 
are metabolically interconnected by high cytokine readings. 
The first is recognized clinically by an elevation of the CRP, 
which is related to obesity2, mainly visceral. This relation 
shows that CRP screening is an important tool to identify 
increased risk in the case of CV morbidity and mortality. 
The prothrombotic state is characterized by increased PAI-
1 and fibrinogen counts,24 both of which are markers of an 
imbalance in the fibrinolytic system, with consequent injury 
to the vascular wall that contributes to vascular disease and 
CV risk. 
The glucose-lowering effect of metformin is attributed 
mainly to decreased hepatic gluconeogenesis and enhanced 
peripheral glucose uptake.12 The United Kingdom 
Prospective Diabetes Study showed that metformin use 
in overweight T2DM patients decreased macrovascular 
morbidity and mortality independent of glycemic control.13 
This suggests that metformin has pleiotropic vascular effects 
that act on endothelial imbalance, probably increasing 
NO bioavailability,16 decreasing atheroma plaque growth, 
improving the atherogenic lipid profile,25 inhibiting lipid 
incorporation into vessel walls, and inhibiting vascular 
smooth muscle cell proliferation.26 Additionally, this drug 
acts directly on chronic heart disease by improving central 
hemodynamics parameters and functional class profiles, 
Table 2 - Laboratory data for both groups at baseline and after treatment
Placebo Metformin
Baseline After treatment Baseline After treatment
FPG (mg/dL) 87.8 [84.7-93.7] 90.9 [85.8-96.8] 93.7 [86.4-97.7] 89.2 [80.8-94.3]*
Post-load PG (mg/dL) 99.9 [88.9-108.9] - 110.3 [99.9-122.7] -
Total cholesterol (mg/dL) 186.42 [165.3-205.5] 199.6 [183.3-229.7] 209.4 [192.2-224.6] 197.3 [179.0-221.1]*
LDL-cholesterol 
(mg/dL)
120.9 [107.6-148.2] 134.9 [119.7-148.9] 131.0 [115.8-156.0] 120.5 [100.6-141.1]**
HDL-cholesterol (mg/dL) 36.2 [35.1-44.0] 39.00 [33.9-47.1] 40.1 [36.2-50.7] 47.1 [34.7-53.8]*
Triglycerides (mg/dL 122.8 [105.9-196.6] 118.37 [97.9-162.8] 162.8 [113.9-206.4] 186.01 [108.5-225.1]
Insulin (µUI/mL) 22.6 [13.0-26.4] 18.0 [9.6-23.8] 11.3 [10.9-17.0]† 12.3 [10.7-18.8]
HOMA-IR 4.08 [2.44-6.06] 3.09 [2.32-5.70] 2.49 [2.26-4.25]† 2.67 [2.13-4.43]
C-RP (mg/dL) 0.68 [0.3-1.2] 0.64 [0.3-1.0] 0.78 [0.3-1.1] 0.80 [0.4-0.9]
Fibrinogen (mg/dL) 282.2 [220.4-323.7] 286.7 [249.6-295.1] 303.9 [217.6-347.6] 290.9 [251.5-301.9]
Data expressed as medians (1st-3rd quartiles). †p<0.05 – comparison between placebo and metformin at baseline. *p < 0.05; ** p < 0.01 – comparisons 
within metformin group
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with a consequent improvement in quality of life.27 This 
contributes new insight to the idea that metformin exerts not 
only vascular protective effects but also cardio-protective 
properties.27-29 
Metformin improved the endothelium-dependent 
vasodilation not only in experimental30 but also in T2DM 
patients.31 Recently, it was suggested that the increased CV 
disease risk in individuals with IGT or T2DM was largely 
driven by the coexistence of multiple metabolic disorders 
rather than by hyperglycemia per se,32 suggesting that the 
identification of clustering of metabolic abnormalities should 
be given more consideration in CV disease prevention. The 
use of antihypertensives and antihyperlipidemic drugs results 
in lower CV disease risk in T2DM subjects and also in non-
diabetic patients, but questions remain regarding the use of 
insulin-sensitizers in subjects who are at high risk of CV 
disease, who have MS and IR, but who still exhibit a normal 
glucose tolerance state. Recently we reported that endothelial 
reactivity was improved by short-term use of metformin in 
persons with MS and normal glucose tolerance,17 but long-
term follow-up trials are lacking.
In disagreement with our negative results, in polycystic 
ovary syndrome and also in well-controlled T2DM with 
MS, it has been reported that a decrease in CRP follows 
metformin treatment,33 and there was a greater decrease 
in CRP in treatment with metformin plus glibenclamide 
compared with the glibenclamide alone.34 Consistent with 
our findings, others21, 35 have demonstrated negative results 
regarding CRP levels. Recently, in non-obese T2DM 
patients, Lund and co-workers also failed to demonstrate 
any effects of metformin on fibrinogen as compared to 
repaglinide treatment.36
The cross-sectional design of the present study does not 
allow us to infer a causal relationship between the variables. 
Our data should be viewed as having a bi-directional 
cause-effect association that necessitates a new view of the 
markers of endothelial activation in the context of metabolic 
disorders and their responses to drugs. This also warrants 
further investigation. The limitations of our study are as 
follows. First, the short-term treatment durations may have 
influenced our endpoints. Although our data may point to 
possible long-term benefits, this should first be tested, before 
we could consider our results to have long-term implications. 
Both groups exhibited higher HOMA-IR and insulin levels 
that were unchanged after treatment, but the metformin 
group exhibited a higher insulin sensitivity as assessed by 
indirect measures at baseline compared to placebo. Whether 
this could have influenced our results is hypothetical and 
cannot be proven, although it may have biased our findings. 
Although metformin improved FPG readings, even in 
the normoglycemic range, the fibrinogen level was in the 
normal range for both groups, and CRP levels were only 
slightly elevated and may even have been lower after the 
treatment period, paralleling our FPG results. It should thus 
be emphasized that our patients were selected according 
to criteria related to low-grade inflammation without any 
degree of IGT, and were possibly at precocious states of 
atherogenesis. Finally, both groups were kept on the same 
diet and underwent the same amount of physical activity 
during the study. Unfortunately, the placebo group gained 
weight, but ideally we would expect weight maintenance 
across both groups. 
CONCLUSIONS
Metformin treatment improved some known risk factors 
for CV diseases, but did not alter levels of fibrinogen or 
CRP in first-degree relatives of T2DM subjects who have 
MS and normal glucose tolerance. Metformin demonstrated 
beneficial effects on the CV disease risk profile in short-
term use. However, taking CRP and fibrinogen as markers 
of endothelium imbalance, we conclude on the basis of 
our findings that these two markers should not be used to 
monitor short-term treatment response to metformin. 
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